Welcome to our dedicated page for Danaher Corporation news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher Corporation stock.
Danaher Corporation (NYSE: DHR) is a globally diversified conglomerate based in Washington, D.C., focusing primarily on life sciences and diagnostics. Founded in 1984 by Stephen and Mitchell Rales, the company has transitioned from a real estate organization into a leading player in the medical, industrial, and commercial products sectors.
Danaher designs, manufactures, and markets a variety of innovative products, particularly scientific instruments and consumables. The company has recently revamped its portfolio by divesting its environmental and applied solutions group, Veralto, in late 2023. This strategic move has allowed Danaher to concentrate its efforts on advancing health through science and technology.
Among Danaher's notable achievements is the acquisition of Abcam plc, which enhances its capabilities in proteomics—an expanding field within life sciences. The company is also known for its contribution to gene-editing therapies through a collaboration with the Innovative Genomics Institute (IGI), aiming to develop CRISPR-based treatments for various diseases.
Danaher's portfolio includes well-known subsidiaries like Beckman Coulter Life Sciences, Integrated DNA Technologies, and Aldevron. These subsidiaries focus on delivering innovative solutions in diagnostics, genomics, and biomanufacturing. For instance, Beckman Coulter's recent partnership with Curiox Biosystems aims to provide automated sample preparation for flow cytometry, enhancing research efficiency.
Financially, Danaher reported better-than-expected revenue in the fourth quarter of 2023, bolstered by strong performance in its life sciences and diagnostics segments. The company's strategic divestitures and acquisitions have positioned it for long-term growth and increased shareholder value.
Danaher’s ongoing projects include a collaboration with Cincinnati Children's Hospital to improve liver organoid technology for drug toxicity screening. This initiative is part of the Danaher Beacons program, which funds pioneering academic research to develop next-generation medical technologies. Another significant collaboration is with Johns Hopkins University, focusing on diagnosing mild traumatic brain injuries (TBI) using advanced biomarker panels.
Overall, Danaher's commitment to scientific excellence, innovation, and continuous improvement makes it a crucial player in advancing healthcare globally. With over 63,000 associates worldwide, Danaher is dedicated to improving quality of life and laying the groundwork for a healthier, more sustainable future.
SCIEX has enhanced its software portfolio, launching the OneOmics suite, which facilitates big data processing in multi-omics research via secure cloud computing. This suite allows researchers to analyze large proteomics and metabolomics datasets significantly faster. Additionally, the Molecule Profiler app aids in identifying and quantifying biopharmaceutical metabolites and impurities. The SCIEX OS software ecosystem, now supporting the ZenoTOF 7600 system, ensures data integrity and streamlines workflows for scientists across multiple labs.
Danaher Corporation (NYSE: DHR) announced its agreement to acquire Aldevron for approximately $9.6 billion, enhancing Danaher's presence in genomic medicine. Aldevron, founded in 1998, specializes in high-quality plasmid DNA, mRNA, and proteins, and will operate as a standalone entity within Danaher’s Life Sciences segment. The acquisition aims to support the development of cell, gene therapies, and vaccines. The transaction is subject to customary regulatory approvals.
On June 7, 2021, Danaher Corporation (NYSE: DHR) announced that its Executive Vice President and CFO, Matt McGrew, will present at the Goldman Sachs Global Healthcare Conference on June 8, 2021, at 2:10 p.m. ET. The presentation will be available via a live webcast on www.danaher.com. Danaher is recognized as a global leader in science and technology, focusing on healthcare and environmental sectors, and operates with around 69,000 employees, all committed to enhancing quality of life.
Danaher Corporation (NYSE: DHR) announced that its Executive Vice President and CFO, Matt McGrew, will present at the Jefferies Healthcare Conference on June 2, 2021, at 1:00 p.m. ET. The presentation will be available via a live webcast on Danaher's official website. Danaher is a leader in science and technology, focusing on solving complex challenges and improving global quality of life. With over 69,000 associates, Danaher operates more than 20 companies across health care, environmental, and applied end-markets.
Danaher Corporation (NYSE: DHR) announced the appointment of A. Shane Sanders to its Board of Directors and Audit Committee, increasing the board size to thirteen members. Sanders, currently Senior Vice President of Business Transformation at Verizon Communications Inc. (NYSE: VZ), has extensive experience in corporate finance, having served in leadership roles since joining Verizon in 1997. His qualifications include a B.S. in Accounting and an M.B.A. His appointment is expected to enhance Danaher's leadership and support its goal of building long-term shareholder value.
Danaher Corporation (NYSE: DHR) has declared a quarterly cash dividend of $0.21 per share on its common stock, payable on July 30, 2021, to shareholders on record as of June 25, 2021. Additionally, the company announced dividends of $11.875 per share for its 4.75% Series A Mandatory Convertible Preferred Stock and $12.50 per share for its 5.00% Series B Mandatory Convertible Preferred Stock, both payable on July 15, 2021, with record dates of June 30, 2021.
Danaher Corporation (NYSE: DHR) will have its President and CEO, Rainer M. Blair, presenting at the Bank of America Healthcare Conference on May 11, 2021, at 2:00 p.m. ET. The presentation will be webcast live on Danaher's official website. Danaher is recognized as a global leader in science and technology, focusing on solving complex challenges across health care, environmental, and applied end-markets. With over 69,000 employees, Danaher operates more than 20 companies unified by the Danaher Business System, dedicated to enhancing quality of life worldwide.
Danaher Corporation (NYSE: DHR) has established a Scientific Advisory Board to bolster its innovation and investment strategies. The Board comprises renowned scientists, including two Nobel laureates, who will aid in assessing M&A opportunities and guiding early-stage investments. Their role involves collaborating with Danaher’s leadership to enhance scientific innovations essential for global health. CEO Rainer Blair emphasized the Board's key role in aligning Danaher’s scientific agenda with evolving healthcare needs. This strategic move aims to strengthen Danaher's competitive edge and accelerate advancements in health technologies.
Danaher Corporation (NYSE: DHR) reported robust Q1 2021 results, showcasing net earnings of $1.7 billion or $2.29 per diluted share, marking a 182.5% year-over-year increase. Revenues surged 58.0% to $6.9 billion, with 30.0% non-GAAP core revenue growth including Cytiva. Operating cash flow reached $1.9 billion, a 126.5% rise year-over-year. Looking ahead, Danaher expects mid-20% non-GAAP core revenue growth for Q2 and high-teens growth for the full year. CEO Rainer M. Blair highlighted strong market performance driven by contributions to COVID-19 related developments.
Danaher Corporation (NYSE: DHR) announced that its first quarter 2021 core revenue growth exceeded expectations, with total revenue growth at approximately 57.0% and non-GAAP core revenue growth including Cytiva at 29.0%. This strong performance was attributed to significant growth in the Life Sciences and Diagnostics segments. The company will discuss these results in its earnings conference call on April 22, 2021. The non-GAAP measures mentioned will aid investors in understanding underlying growth trends.
FAQ
What is the current stock price of Danaher Corporation (DHR)?
What is the market cap of Danaher Corporation (DHR)?
What does Danaher Corporation specialize in?
Who founded Danaher Corporation and when?
Where is Danaher Corporation headquartered?
What recent divestiture has Danaher Corporation made?
What are some of Danaher's notable subsidiaries?
What recent acquisition has enhanced Danaher's capabilities in proteomics?
What is the Danaher Beacons program?
What collaboration is Danaher involved in to improve liver organoid technology?
What is the focus of Danaher's partnership with Johns Hopkins University?
How does Danaher contribute to the field of gene-editing therapies?
